Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | terminated | Phase 1 | 6 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 |
| Nov 24, 2021 |
| clinicaltrials |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 74 | Daiichi SankyoINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | terminated | Phase 1 | 2 | Medical College of WisconsinOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | terminated | Phase 1 / Phase 2 | 1 | Fox Chase Cancer CenterOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02370888 | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease(UF-BMT-MRD-101) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | terminated | Phase 1 | 12 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01747499 | Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | terminated | Phase 1 / Phase 2 | 54 | Washington University School of MedicineOTHER | 1 | Oct 16, 2019 | clinicaltrials |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML | terminated | Phase 1 | 16 | Boehringer IngelheimINDUSTRY | 2 | Feb 8, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | terminated | Phase 1 | 50 | PlexxikonINDUSTRY | 1 | Dec 24, 2018 | clinicaltrials |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | terminated | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 28 | CelgeneINDUSTRY | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00356928 | Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies | terminated | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01795924 | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome(AML/MDS) | terminated | Phase 1 / Phase 2 | 13 | Biosuccess Biotech Co., Ltd.INDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT00295880 | Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 28, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01207076 | AHN-12 Biodistribution in Advanced Leukemia | terminated | Phase 1 | 8 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00376519 | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00618696 | Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | terminated | Phase 1 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00725062 | Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01085656 | A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS | terminated | Phase 1 | 18 | University of FloridaOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01034592 | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia | terminated | Phase 1 | 2 | Jason Robert GotlibOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00555048 | Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | terminated | Phase 1 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00569179 | A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | terminated | Phase 1 | 1 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00800150 | Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment | terminated | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Mar 9, 2022source: clinicaltrials